During the past decade, Q-Pharm conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 3 clinical trials were completed, i.e. on average, 30% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Q-Pharm" #1 sponsor was "Medicines for Malaria Venture" with 2 trials, followed by "Zafgen, Inc." with 2 trials sponsored, "Adjuvance Technologies, Inc." with 1 trials sponsored, "Altimmune, Inc." with 1 trials sponsored and "CSL Limited" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Q-Pharm" #1 collaborator was "Clinical Network Services (CNS) Pty Ltd" with 1 trials as a collaborator, "Q-Pharm Pty Limited" with 1 trials as a collaborator, "QIMR Berghofer Medical Research Institute" with 1 trials as a collaborator, "Queensland Institute of Medical Research" with 1 trials as a collaborator and "Tunitas Therapeutics Australia Pty Ltd" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Q-Pharm" are "Malaria" (2 trials), "Allergy and Immunology" (1 trials), "Asthma" (1 trials), "Chronic Obstructive Pulmonary Disease" (1 trials) and "Healthy" (1 trials). Many other conditions were trialed in "Q-Pharm" in a lesser frequency.

Most popular intervention types in "Q-Pharm" are "Drug" (9 trials), "Biological" (3 trials), "Combination Product" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "0.1 mg/kg epsi-gam or placebo (6:2)" (1 trials), "0.3 mg/kg epsi-gam or placebo (6:2)" (1 trials), "1.0 mg/kg epsi-gam or placebo (6:2)" (1 trials) and "10 mg/kg epsi-gam or placebo (6:2)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Q-Pharm" are 12 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Q-Pharm". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Q-Pharm, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Q-Pharm, 9 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".